The Challenge of Change - Managing Excipients Control
Colorcon
16-Nov-2010 - Biogen Idec has started shedding development programmes to stay in line with the restructuring plan and job cuts it announced earlier this month.
16-Nov-2010 - The HIV company, ViiV, set up by GlaxoSmithKline and Pfizer in 2009, might be spun off and floated in an initial public offering.
16-Nov-2010 - According to IMS Health Research, US sales of oncology drugs are slowing despite more firms promising exciting cancer drug developments.
15-Nov-2010 - in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Aqua Pharmaceuticals, Algeta ASA and Amarin.
10-Nov-2010 - US drugmaker Eli Lilly said it will buy Avid Radiopharmaceuticals to expand its neuroscience diagnostics business.
09-Nov-2010 - Dutch biopharmaceutical company Crucell expects its operating loss for 2010 to be in the €20-25 million range, citing costs associated with microbial contamination at its Shingal facility in Korea as a key factor.
09-Nov-2010 - in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the departure of an FDA foreign inspections official and the search for a leader of the EMA.
08-Nov-2010 - Novartis is teaming up with Arab Company for Pharmaceutical Products (Arabio) to provide Saudi Arabia and surrounding regions with vaccines for common diseases.
03-Nov-2010 - in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Agensys, Unigene, Medivir and Apitope.
02-Nov-2010 - Biopharm are increasingly assessing the threat counterfeiting and diversion pose to emerging biotechs when planning an acquisition, according to a white paper.
02-Nov-2010 - Pfizer has widen its recall of the cholesterol-fighting drug, Lipitor, after two more complaints of a musty odour emanating from the product’s bottles.
28-Oct-2010 - Novartis will invest $600m to expand its US R&D campus over the next five years to strengthen its position in US development hotspot.
28-Oct-2010 - Overseas FDA offices have realised immediate benefits but strategic planning is needed to ensure the ventures, critical aspects of the agency’s ability to ensure drug quality, are long-term successes according to the GAO.
27-Oct-2010 - UK-drugmaker GlaxoSmithKline (GSK) must pay $750m to settle a law suit criticising manufacturing practices at plant in Cidra, Puerto Rico that was shut down in 2009.
27-Oct-2010 - PhRMA says a new Puerto Rico law to tax offshore manufacturers will “dramatically hinder” biopharma companies.
26-Oct-2010 - in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Jennerex, a new KV subsidiary and Takeda.
25-Oct-2010 - US Biotechnology firm Genzyme predicts 2011 earnings in $4.30 to $4.60 range, which would make it worth $89 per share or $22.7bn.
20-Oct-2010 - Sanofi Aventis has been given the go ahead to pursue US biotech Genzyme by the country’s antitrust authorities.
20-Oct-2010 - Eli Lilly has unveiled plans to close its Singapore R&D centre by the end of the year and relocate discovery operations to its global headquarters in the US.
19-Oct-2010 - A week of global anti-counterfeiting law enforcement coordinated by Interpol led to the shutdown of 290 websites, seizure of 11,000 packages and confiscation of 1m pills.
18-Oct-2010 - The FDA and PAHO are collaborating to develop an information hub for medical products and regulatory processes in the Americas.
18-Oct-2010 - in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including board elections at ISPE and appointments at Advaxis and Asubio.
13-Oct-2010 - IMS Health predicts that global drug sales will increase 5 to 7 per cent next year, driven by development of innovative pharmaceuticals and growth of emerging markets.
12-Oct-2010 - in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at NormOxys, Caraco, Shire and ChemWorth.
11-Oct-2010 - Sanofi Aventis says eliminating 1,700 jobs in US will help it concentrate resources on business development, investment in late-stage development projects and will position it for growth after patent expiry.